manufacturing deficiency

Class action lawsuit filed against Inovio Pharmaceuticals for allegedly making false statements about manufacturing deficiencies and overstating regulatory prospects, triggering 24.45% stock decline.

Rosen Law Firm urges Inovio investors with $100K+ losses to file by April 7 deadline in securities class action alleging false manufacturing and regulatory statements.

$INO faces securities fraud lawsuit alleging false statements about INO-3107 regulatory timeline and CELLECTRA device manufacturing. Stock fell 24.45% in December 2025 after FDA rejected accelerated review.

Inovio shareholders with $100K+ losses must meet April 7 deadline to join securities lawsuit alleging false statements about CELLECTRA device and INO-3107 FDA timeline.

Rosen Law Firm urges Inovio Pharmaceuticals investors with losses exceeding $100K to file claims before April 7, 2026 deadline in ongoing securities class action lawsuit.

Rosen Law Firm alerts $INO investors of April 7, 2026 deadline to join class action over alleged false statements regarding manufacturing and regulatory prospects.

Rosen Law Firm seeks lead plaintiffs in securities class action against Inovio Pharmaceuticals for alleged misstatements on device defects, regulatory prospects, and product timelines. Lead plaintiff deadline: April 7, 2026.

Class action lawsuit filed against Inovio Pharmaceuticals ($INO) for allegedly making false statements about INO-3107 treatment and manufacturing capabilities, causing significant stock declines.

Inovio Pharmaceuticals faces a securities class action over allegedly false statements regarding manufacturing capabilities and regulatory prospects for INO-3107, following FDA's December 29 accelerated approval rejection.

Rosen Law Firm urges $INO investors to join class action lawsuit alleging false statements about manufacturing deficiencies and regulatory prospects.

Class action lawsuit filed against $INO for allegedly false statements about INO-3107 treatment and CELLECTRA device. Lead plaintiff deadline is April 7, 2026.

Pomerantz files class action against Inovio Pharmaceuticals for alleged securities fraud related to false FDA approval statements and concealed manufacturing deficiencies.

Inovio Pharmaceuticals faces class action lawsuit over alleged false statements regarding manufacturing defects and regulatory prospects after FDA rejected accelerated approval, causing 24% stock decline.

Inovio Pharmaceuticals faces securities lawsuit alleging false statements about its CELLECTRA device and regulatory prospects. Investors who purchased stock between October 2023-December 2025 may qualify for compensation.

Rosen Law Firm files class action lawsuit against Inovio Pharmaceuticals for allegedly misrepresenting manufacturing capabilities and overstating product development prospects, urging investors to act before deadline.

Rosen Law Firm sues Inovio Pharmaceuticals for allegedly making false statements about manufacturing capabilities and regulatory timelines, causing investor losses through inflated stock prices.

Rosen Law Firm files securities class action against Inovio Pharmaceuticals for allegedly making false statements about manufacturing deficiencies and regulatory prospects between October 2023 and December 2025.

Inovio Pharmaceuticals faces securities lawsuit over false statements about manufacturing and regulatory prospects. FDA rejected accelerated approval for lead drug candidate, causing 24% stock drop.

Inovio Pharmaceuticals faces class action lawsuit for allegedly misleading investors about device manufacturing capabilities and regulatory delays, leading to 24% stock decline.